SCHEMBL954159

SCHEMBL954159

COc1ccccc1-c1nccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
HPGD P15428 1/20 0.54
ADORA2A P29274 2/20 0.51
SCN9A Q15858 4/20 0.51
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
GAA P10253 1/20 0.47
CYP2A6 P11509 1/20 0.46
UGCG Q16739 1/20 0.45
MAPT P10636 3/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
EGFR P00533 1/20 0.44
PDE10A Q9Y233 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14341090 0.88 CYP1A2 (0.47) ALDH1A1SMN1; SMN2HPGDADORA2ASCN9A
SCHEMBL28431110 0.85 SCN9A (0.48) ALDH1A1SMN1; SMN2HPGDSCN9AKDM4E
SCHEMBL29137491 0.84 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDADORA2ASCN9A
SCHEMBL9097189 0.81 PDE5A (0.49) ALDH1A1HPGDSCN9AKDM4ELMNA
SCHEMBL7642915 0.79 MAPT (0.66) ALDH1A1SMN1; SMN2HPGDSCN9AKDM4E
SCHEMBL158912 0.78 BCHE (0.58) ALDH1A1SMN1; SMN2HPGDKDM4EGAA
SCHEMBL29986041 0.78 BCHE (0.58) ALDH1A1SMN1; SMN2HPGDKDM4EGAA
SCHEMBL7004339 0.78 MAOA (0.46) ALDH1A1SMN1; SMN2HPGDSCN9AKDM4E
SCHEMBL3648742 0.77 CYP2A6 (0.55) ALDH1A1SMN1; SMN2HPGDADORA2ASCN9A
SCHEMBL7445924 0.77 CYP2A6 (0.40) ALDH1A1SMN1; SMN2HPGDSCN9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 EP disclosed
CN-103476781-A Novel tetradentate platinum complexes UNIVERSAL DISPLAY CORP 2013-12-25 CN disclosed
CN-101631793-B Electroluminescent metal complexes of benzotriazoles BASF SE 2013-12-25 CN disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
WO-2011006353-A1 LUMINESCENT GOLD(III) COMPOUNDS CONTAINING BIDENTATE LIGAND FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION THE UNIVERSITY OF HONG KONG (CN) 2011-01-20 WO disclosed
CN-101631793-A Electroluminescent metal complexes of benzotriazoles BASF SE 2010-01-20 CN disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed
US-20090039776-A1 ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME CANON KABUSHIKI KAISHA (JP) 2009-02-12 US disclosed
CN-100375749-C Luminescence device and display apparatus CANON KK (JP) 2008-03-19 CN disclosed
EP-1868998-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS Insa Rouen (FR) 2007-12-26 EP disclosed
EP-1731507-A1 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents Institut National des Sciences Appliquees de Rouen (INSA) (FR) 2006-12-13 EP disclosed
CN-1285601-C Light emitting device and display CANON KK (JP) 2006-11-22 CN disclosed
WO-2006103120-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2006-10-05 WO disclosed
CN-1781925-A Luminescence device and display apparatus CANON KK (JP) 2006-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP ALDH1A1 1663/4885SMN1; SMN2 403/4885HPGD 93/4885
US-20090039776-A1 ORGANOMETALLIC COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT USING SAME LAGE3, ORC3, INTS9 ALDH1A1 251/4885SMN1; SMN2 1885/4885HPGD 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.